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Monitoring recombinant factor VIIa treatment: efficacy depends
on high levels of fibrinogen in a model of severe dilutional
coagulopathy
Abstract
OBJECTIVES: Recombinant activated factor VII (rFVIIa) is increasingly being given to treat massive
bleeding. However, there is no clear guidance on which patients are suitable for treatment and how the
effects of treatment should be monitored. The aim of this in vitro study was to assess the coagulation
status of severely hemodiluted blood samples before and after treatment with therapeutic doses of
rFVIIa and/or fibrinogen with 2 viscoelastic point-of-care coagulation analyzers: ROTEM (Pentapharm
GmbH, Munich, Germany) and Sonoclot (Sienco Inc, Arvada, CO). DESIGN: Laboratory study.
SETTING: Research coagulation laboratory. PARTICIPANTS: Ten healthy male volunteers without
hereditary or acquired coagulation disorders. INTERVENTIONS: Blood samples were obtained. After
severe hemodilution with albumin 5%, therapeutic doses of rFVIIa and/or fibrinogen were added, and
the coagulation status was assessed with new 1:1,000 diluted tissue factor-activated tests from ROTEM
and Sonoclot. MEASUREMENTS AND MAIN RESULTS: The administration of therapeutic doses of
rFVIIa to hemodiluted samples shortened the initiation phase of coagulation only. Isolated fibrinogen
administration to physiologic levels improved both the initiation of coagulation as well as clot formation
and strength. Combined fibrinogen and rFVIIa administration further improved both effects.
CONCLUSIONS: ROTEM and Sonoclot were able to monitor the effects of rFVIIa and fibrinogen
administration with 1:1,000 diluted tissue factor-activated tests. The efficacy of rFVIIa was largely
dependent on the presence of high levels of fibrinogen in reversing this severe dilutional coagulopathy.
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ABSTRACT 
Objectives: Recombinant activated factor VII (rFVIIa) is increasingly being given to treat 
massive bleeding. However, there is no clear guidance on which patients are suitable for 
treatment and how the effects of treatment should be monitored. The aim of this in vitro 
study was to assess the coagulation status of severely hemodiluted blood samples 
before and after treatment with therapeutic doses of rFVIIa and or fibrinogen with two 
viscoelastic point of care coagulation analyzers, ROTEM and Sonoclot. 
Design: Laboratory study. 
Setting: Research coagulation laboratory. 
Participants: 10 healthy male volunteers without hereditary or acquired coagulation 
disorders. 
Interventions: Blood samples were obtained. After severe hemodilution with albumin 
5% therapeutic doses of rFVIIa and / or fibrinogen were added and the coagulation 
status assessed with new 1:1,000 diluted tissue factor activated tests from ROTEM and 
Sonoclot. 
Measurements and Main Results: Administration of therapeutic doses of rFVIIa to 
hemodiluted samples shortened the initiation phase of coagulation only. Isolated 
fibrinogen administration to physiological levels improved both the initiation of 
coagulation as well as clot formation and strength. Combined fibrinogen and rFVIIa 
administration further improved both effects.  
Conclusions: ROTEM and Sonoclot were able to monitor the effects of rFVIIa and 
fibrinogen administration with the new 1:1,000 diluted tissue factor activated tests 
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Furthermore, efficacy of rFVIIa was largely dependent on the presence of high levels of 
fibrinogen in reversing this severe dilutional coagulopathy. 
 
 
 
Key words 
Recombinant activated factor VII, fibrinogen concentrate, hemodilution, dilutional 
coagulopathy, thrombelastography, thrombelastometry, ROTEM, Sonoclot Analyzer. 
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INTRODUCTION 
Recombinant activated factor VII (rFVIIa) is increasingly being given on a 
compassionate basis to control severe bleeding1 and has been shown to result in a 
significant reduction in red blood cell transfusion in severe blunt trauma.2 Although 
consensus guidelines for use of rFVIIa have been published recently,3,4 a paucity of data 
from randomized controlled trials limit the strength and scope of these 
recommendations. No specific method is currently available to indicate the need for 
rFVIIa or to monitor its efficacy. Therefore, the administration of rFVIIa in patient with 
massive hemorrhage still depends largely on clinical judgment.5 Viscoelastic techniques 
like thrombelastography/thrombelastometry or Sonoclot analysis appear to be highly 
desirable and have shown some promising results.6-8 Coagulation is assessed in whole 
blood allowing coagulation factors to interact with red cells and platelets. rFVIIa 
increases thrombin formation by tissue factor dependent and – independent activation of 
factor X on the surface of platelets.9 To study effects of rFVIIa, blood samples need to 
be activated with minute amounts of tissue factor for best sensitivity.10,11 Presence of 
high amounts of tissue factor may directly activate the coagulation cascade (bypassing 
agent) and effects of rFVIIa may no longer be monitored.11 
Modern practice of coagulation management is based on rapid diagnosis of the 
patient’s coagulation status, specific component therapy, and monitoring of the pro-
coagulant treatment.12 Measuring clotting factors during progressive hemodilution 
showed that fibrinogen is the first factor to become critically low.13,14 Fibrinogen is a key 
coagulation factor (substrate to form a clot) and isolated fibrinogen substitution in severe 
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models of dilutional coagulopathy resulted in a significantly improved clot strength and 
reduced blood loss.15-18 
The aim of this in vitro study was to determine the efficacy of rFVIIa in a model of 
severe dilutional coagulopathy by two different viscoelastic point of care (POC) 
coagulation analyzers (ROTEM system, Pentapharm GmbH, Munich, Germany and the 
Sonoclot Analyzer, Sienco Inc. Arvada, CO, USA). Our hypothesis was that rFVIIa may 
only reverse severe dilutional coagulopathy in presence of sufficient fibrinogen levels. 
METHODS 
With institutional approval blood was withdrawn from 10 healthy volunteers. 
Exclusion criteria were hereditary or acquired coagulation disorders including 
pharmacologically induced coagulopathies i.e., treatment with any anticoagulants or 
antiplatelet drugs 14 days before blood withdrawal.  
Blood Sampling 
Fifty millilitres of venous blood were sampled after application of minimum stasis 
from the antecubital fossa via a 21-gauge needle. The blood was filled into citrated 
tubes (sodium citrate, 0.109 mol/l; BD Vacutainer, Becton Dickinson) and the initial tube 
was discarded before collection of the test tubes to avoid tissue factor contamination. An 
extra tube (EDTA; BD Vacutainer, Becton Dickinson) was obtained for whole blood 
count and platelet measurement. 
Hemodilution 
In order to mimic a scenario of maximum dilution of clotting factors but maintaining a 
minimally required hemoglobin concentration and platelet count, we processed our 
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samples to obtain platelet-rich plasma (PRP; centrifugation at 80 g for 8 min). PRP was 
carefully collected and the remaining sample re-centrifuged (400 g for 3 min) to further 
concentrate the red blood cells (RBC). The supernatant (remaining plasma and buffy 
coat) was discarded and the RBC washed twice with 0.9% normal saline. Then, PRP 
was diluted 1:20 with albumin 5% (ZLB Behring, Berne, Switzerland; sodium citrate, 
0.109 mol/l was added to the albumin solution prior to the dilution of PRP) and washed 
RBC were added to obtain a final targeted hematocrit of 20%. Albumin 5% was chosen 
in this hemodilution model because it has been shown previously to have the least 
adverse effect on hemostasis compared to other colloids.19,20 
Treatment of hemodiluted blood samples with rFVIIa and fibrinogen 
The reconstituted blood samples were treated with a therapeutic dose of rFVIIa 
(Novo Nordisk, Copenhagen, Denmark; final concentration 1.4 μg/ml) corresponding to 
a clinical dose of 100 μg/kg bodyweight. Furthermore, diluted blood samples were 
treated with fibrinogen (Calbiochem, San Diego, CA; final targeted concentration 2 g/l) 
alone or combined with rFVIIa. Because the maximum effect of rFVIIa was seen in blood 
samples treated with fibrinogen, a dose response of rFVIIa was then performed in these 
blood samples.  
Coagulation Analysis 
Whole blood coagulation analyses were done with the rotation thrombelastometry 
ROTEM (Pentapharm GmbH, Munich, Germany) and the Sonoclot Coagulation and 
Platelet Function Analyzer (Sienco Inc. Arvada, CO, USA). Both technologies have been 
described in detail elsewhere.21,22 Briefly, the measurements are based on the detection 
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of viscoelastic changes of a blood sample after activation with different coagulation 
activators (1:1,000 diluted tissue factor was used for this study).  
ROTEM measures and graphically displays the time until initial fibrin formation 
(clotting time, CT: denoted as clot initiation), the kinetics of fibrin formation and clot 
development (alpha angle, α: denoted as clot propagation) and the ultimate clot strength 
and stability (maximum clot firmness, MCF).16,23-25 In order to study thrombus 
generation, modified ROTEM parameters (based on the original tracing) have been 
introduced recently: maximum velocity of clot formation (maximum rate of thrombus 
generation, MaxVel), time to reach MaxVel (time to maximum thrombus generation, t-
MaxVel) and total thrombus generation (area under the curve, AUC).11,23 These 
parameters are supposed to be more sensitive to rFVIIa than standard ROTEM 
parameters.26 The Sonoclot Analyzer provides information on the entire hemostasis 
process both in a qualitative graph, known as Sonoclot Signature and as quantitative 
results: the activated clotting time (ACT), the clot rate (CR) and the platelet function. The 
ACT is the time from the activation of the sample until the beginning of a fibrin formation. 
Besides providing information on the initiation phase of coagulation, the Sonoclot 
Analyzer also measures the kinetics of fibrin formation and clot development, expressed 
as CR (i.e., the maximum slope of the Sonoclot Signature during initial fibrin 
polymerization and clot development). Furthermore, the Sonoclot Analyzer analyses the 
timing and quality of the clot retraction and calculates the function of the platelets 
accordingly.25 
All analyses were performed at 37°C in duplicate using 1:1,000 diluted tissue factor 
activated tests provided by the manufacturer (for ROTEM: tif-TEM, Pentapharm GmbH, 
Munich, Germany; for Sonoclot: microPT, Sienco Inc., Arvada, CO, USA). Re-
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calcification of blood samples was done by adding 20 µl of 0.25 M CaCl2 to the test 
cuvettes containing 20 μl of coagulation activator. Subsequently, 330 µl of blood 
specimen was dispensed with a pipette, mixed and analyzed. 
Routine coagulation tests included platelet count, prothrombin time (PT), activated 
partial thromboplastin time (aPTT) and fibrinogen concentration determined by Clauss 
method. 
Data analysis, Statistics 
StatView for Windows version 5.01 (SAS Institute Inc, Cary, NC) and SPSS for 
Windows Release 12.0.2 (SPSS Inc, Chicago, IL) were used to perform the statistical 
analyses. ANOVA with post-hoc Bonferroni-Dunn correction was done to compare the 
different conditions of the blood samples (p value adjusted to 5 [effect of rFVIIa and 
fibrinogen on hemodiluted blood samples] and 4 comparisons [dose response of rFVIIa], 
respectively). Test variability was calculated as the % difference between duplicate 
measurements in relation to the mean of duplicate measurements. Results are given as 
mean±SD, p<0.05 was considered significant. 
RESULTS 
Venous blood was obtained from 10 male donors (age = 35.5±7.5 years). They were 
non-smokers, had no history of abnormal bleeding and presented without a coagulation 
disorder or anemia (Table 1). 
In-vitro hemodilution 
Diluting blood samples according to our model resulted in a final hematocrit of 19% 
on average and significantly impaired standard coagulation values (Table 1). ROTEM 
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and Sonoclot variables reflected the severe hemodilution: ROTEM’s CT and t-MaxVel 
significantly increased, whereas all other variables (angle α, MCF, MaxVel and AUC) 
significantly decreased. The same effect was observed for the Sonoclot variables ACT 
and CR (Figure 1,2). 
Effect of rFVIIa and fibrinogen on hemodiluted blood samples 
Administration of therapeutic doses of rFVIIa to hemodiluted samples significantly 
shortened PT (-31±11 sec), ROTEM’s CT (-180±90 sec) and Sonoclot’s ACT (-88±180 
sec). However, no effects on ROTEM’s angle α, MCF and Sonoclot’s CR were observed 
(Figure 1,2).  
Single administration of fibrinogen to diluted samples resulted in a final concentration 
of fibrinogen of 2.0±0.3 g/l as determined by the Clauss method. Compared to 
hemodiluted blood samples, fibrinogen substitution decreased PT significantly by -12±7 
sec. Furthermore, all ROTEM and Sonoclot variables improved significantly (Figure 
1,2): There was a reduction of CT, t-MaxVel and ACT values combined with an increase 
of angle α, MCF, MaxVel, AUC and CR values. 
Combined application of rFVIIa and fibrinogen further reduced PT significantly (-15±9 
sec). ROTEM’s CT and t-MaxVel significantly decreased. Angle α, MCF, MaxVel and 
AUC significantly increased. A similar effect was observed for the Sonoclot variables 
ACT and CR (Figure 1,2).  
Dose response of rFVIIa  
Because administration of fibrinogen was necessary for rFVIIa to show an effect in 
our dilutional model, a dose response in samples containing fibrinogen was performed. 
ROTEM’s CT and Sonoclot’s ACT improved equally in all doses studied, even at the 
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lowest dose. ROTEM’s angle α, MCF and Sonoclot’s CR showed comparable results at 
half of the recommended dose compared to the recommended dose, but the pro-
coagulant effect was lost at a quarter of the recommended dose. Again, the new 
ROTEM variables did follow the trend of the CT, angle α and MA (Table 2).  
Test variability 
Overall ROTEM test variability was 14±14% for CT, 9±11% for angle α, 10±12% for 
MCF, 13±14% for t-MaxVel, 9±13% for MaxVel and 10±16% for AUC.. For the Sonoclot 
Analyzer test variability was 9±18% for ACT and 10±18% for CR.  
DISCUSSION 
The present study investigated the effects of administration of rFVIIa and fibrinogen 
in an in vitro hemodilution model. The ROTEM and Sonoclot Analyzer were able to 
monitor the pro-coagulant effects of rFVIIa and fibrinogen administration with diluted 
tissue factor activated tests, tif-TEM and MicroPT. Interestingly, rFVIIa required high 
concentrations of fibrinogen in order to improve the severe coagulopathy.  
In the initial period of fluid resuscitation of patients with massive hemorrhage, large 
amounts of crystalloids, colloids, and universal 0 type RBC are typically infused. Testing 
and preparing of blood coagulation products (e.g., fresh frozen plasma, cryoprecipitate, 
and platelets) is time consuming. Therefore, a severe dilutional coagulopathy may 
develop in the early period of massive transfusion because these coagulation products 
may not be readily available. Our dilutional model aimed at reproducing an extreme 
dilutional coagulopathy but keeping minimal hemoglobin and platelet levels (Table 1). In 
this model of severe hemodilution, rFVIIa only improved the initiation phase of 
coagulation (PT; CT; ACT). By contrast, isolated fibrinogen administration improved not 
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only the initiation of coagulation also formation and strength of the developing clot (α-
angle, MCF; CR). Combined application of rFVIIa and fibrinogen further improved the 
coagulation status of the sample significantly. 
There is a growing body of evidence suggesting that aggressive fibrinogen 
substitution may significantly reverse dilutional coagulopathy, thereby reducing blood 
loss after severe injury.15-18 Substitution of fibrinogen in our dilutional model up to 2 g/l 
significantly improved the coagulation status of the blood samples. Fibrinogen is the 
substrate to form a clot thereby explaining its key role in coagulation. Furthermore, 
combining fibrinogen and prothrombin complex concentrate (factor II, VII, IX, X) 
administration has recently been shown to further improve dilutional coagulopathy 
resulting in normalization of coagulation parameters measured.27 
rFVIIa treatment is currently approved for patients with congenital or acquired 
hemophilia with antibodies to Factor VIII or IX (United States and Europe), factor VII 
deficiency and Glanzmanns thrombasthenia (Europe). However, VIIa is increasingly 
used in off-label indications to control severe bleeding.1 Because rFVIIa is a very potent 
pro-hemostatic agent, there is concern that rFVIIa may cause thromboembolic adverse 
events resulting in serious morbidity and mortality.28,29 Therefore, the risks and benefits 
have to be carefully outweighed before each single administration. In cardiac surgery for 
example, there is little evidence to suggest a prophylactic use of rFVIIa. However, in 
patients experiencing refractory postoperative hemorrhage, the use of rFVIIa seems 
promising and relatively safe although definitive evidence from randomized controlled 
trials is lacking.30,31 Doses of rFVIIa ranging from 20-200 μg/kg have been given with 
varying success and 90-120 μg/kg of rFVIIa is generally considered the recommended 
initial dose.3,4,32 Our results in severe hemodilution suggest that half of the 
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recommended dose (~50 μg/kg, final concentration of 0.7 μg/ml) has similar effect as 
compared to the full dose. Further decreasing the administered dose however resulted 
in a loss of the pro-coagulant effect of rFVIIa. 
Our data are in accordance with previously published reports showing that isolated 
rFVIIa administration has failed to correct coagulopathy in an in vitro model of 
hemodilution.33 Furthermore, rFVIIa treatment has shown minimal effects on blood loss 
after major hemorrhage in animals with severe dilutional coagulopathy.34,35 The concept 
of rFVIIa is to activate coagulation at sites of tissue factor exposure. The resulting 
thrombin burst then leads to the formation of a fibrin clot, provided sufficient fibrinogen 
levels and platelets are present. In order to get the maximum effect of rFVIIa, consensus 
guidelines recommend first that the bleeding source should be controlled as best as 
possible and second that patients be optimized prior to administration of rFVIIa targeting 
a hematocrit >24%, fibrinogen >0.5-1 g/l, platelets >50-100,000 x 109 /l and pH ≥7.2.3,4,32 
In our dilutional model however, rFVIIa improved the coagulation status significantly 
even with lower platelets (32,000 x 109 /l) if prior fibrinogen substitution was performed. 
ROTEM and the Sonoclot Analyzer are both viscoelastic POC coagulation analyzers. 
They measure the entire clotting process starting with fibrin formation and continue 
through to clot retraction and lysis at the bedside with minimal time delays. Furthermore, 
physiological clot development is depicted as a result of whole blood analysis of the 
coagulation status. ROTEM measures the shear elasticity of the blood sample. The 
rotation of the pin begins to be impaired after fibrin-platelet bonding has linked the cup 
and pin together. The strength of these fibrin-platelet bonds affects the magnitude of the 
pin motion. Thus, the output is directly related to the strength of the formed clot. The 
Sonoclot Analyzer on the other hand uses a different approach. A plastic probe is 
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immersed and oscillates vertically in the sample. The output is sensitive to viscosity and 
monitors viscosity changes that occur during initiation of coagulation and clot 
development. 
Viscoelastic POC analyzers have been used to evaluate the effects of hemostatic 
agents, such as rFVIIa.6-8 In theses studies, thrombelastography/thrombelastometry 
seems to be a promising methods for characterization of phenotypic variance amongst 
patients as well as in detection of the individual response to rFVIIa prior and following 
rFVIIa administration. Presence of high amounts of tissue factor may directly activate 
the coagulation cascade (bypassing agent) and effects of rFVIIa may no longer be 
monitored. Therefore, activation with minute amounts of tissue factor has been 
recommended to visualize the particular signature in different coagulopathies, and 
particularly to demonstrate the rFVIIa response.11 
Recently, modified parameters of the thrombelastograph/thrombelastometry have 
been introduced based on the first derivative of the original tracing and been shown to 
correlate closely with thrombin formation.11,23 These parameters, time to maximum 
thrombus generation (t-MaxVel) maximum rate of thrombus generation (MaxVel), and 
total thrombus generation (area under the curve, AUC) are supposed to be more 
sensitive to rFVIIa treatment than standard thrombelastography/thrombelastometry 
parameters.26 However, these modified parameters did not better perform in monitoring 
rFVIIa administration in the present study compared to ROTEM’s conventional α-angle 
and MCF as well as Sonoclot’s CR. 
Interpretation of the data presented has to be within the limitations of an in vitro 
investigation with cautious extensions of the findings into clinical application only. In vitro 
coagulation studies may not necessarily reflect in vivo conditions because the effects of 
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tissue damage, endothelial injury, and physiological reactions to correct coagulation are 
missing in vitro. Furthermore, the study was performed with citrated blood samples of 
healthy male volunteers only. Additionally, we chose to study severe hemodilution with 
albumin 5% to have minimal effects on coagulation other then dilutional. It is likely that in 
vitro hemodilution with other colloids or crystalloids will show different results. 
Nevertheless, the present study provides some mechanistic insights into how rFVIIa is 
dependent on sufficient concentration of fibrinogen and investigates for the first time the 
two POC coagulation analyzers ROTEM and Sonoclot in this indication. 
In summary, administration of rFVIIa alone resulted in our in vitro model of severe 
hemodilution in a shortened initiation phase of coagulation as detected by ROTEM and 
Sonoclot. Isolated fibrinogen administration to physiological concentrations improved 
both the initiation of coagulation as well as clot formation and strength. Combined 
fibrinogen and rFVIIa administration further improved both effects significantly. These 
data suggest that fibrinogen is a key component in the coagulation process and that 
adequate levels of fibrinogen should be present before considering the administration of 
rFVIIa. However, further studies in vivo are required to confirm these findings. 
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FIGURE LEGENDS 
Figure 1. Effects of recombinant factor VIIa (rFVIIa) and or fibrinogen substitution 
on ROTEM and Sonoclot variables. The two phases of coagulation, initiation of 
coagulation (1A) and clot formation, strength and stability (1B) are analyzed by the 
ROTEM and Sonoclot Analyzer. CT = clotting time, ACT = activated clotting time, α = 
angle alpha, MCF = maximum clot formation, CR = clot rate.  
#, p<0.05: effect of modified hemodilution; §, p<0.05: effect of therapeutic doses of 
rFVIIa; °, p<0.05: effect of fibrinogen administration; *, p<0.05: CT vs. ACT. 
 
Figure 2. Effects of recombinant factor VIIa (rFVIIa) and fibrinogen on additional 
ROTEM variables. t-MaxVel = time to reach MaxVel (time to maximum thrombus 
generation), MaxVel =  maximum velocity of clot formation (maximum rate of thrombus 
generation), AUC = area under the curve (total thrombus generation). 
#, p<0.05: effect of modified hemodilution; §, p<0.05: effect of therapeutic doses of 
rFVIIa; °, p<0.05: effect of fibrinogen administration. 
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TABLES 
 
 
 
 
Table 1: Hematocrit and standard coagulation variables before and after hemodilution. 
___________________________________________________________________ 
  Baseline Hemodilution  
___________________________________________________________________ 
HCT  % 42±3 19±2 
PT sec 10±1 74±20 
aPTT  sec 42±5 >180 
Platelets  103 mm-3 178±62 29±14 
Fibrinogen  g l-1 2.31±0.47 0.15±0.21 
___________________________________________________________________ 
HCT = Hematocrit, PT = Prothrombin time, aPTT = Activated partial thromboplastin time 
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FIGURE 4 
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